Case Study of a 54-Year-Old Woman With HER2+ Metastatic Breast Cancer and Brain Metastases: Optimal Treatment Approaches

Video content above is prompted by the following questions:

• Patient Case: A 54-year-old woman with HER2+ metastatic breast cancer and brain metastases
  • Please describe your initial impressions of this case. How might you have treated this patient in your practice?
• Per the NCCN guidelines, what is the preferred treatment approach for this patient/patients with systemic and CNS progression?
• In which lines of therapy do the NCCN guidelines recommend using the tucatinib + trastuzumab + capecitabine regimen for patients with brain metastases?
• Please discuss the differences between active and stable brain metastases and how these factors influence your treatment decisions.
  • At what points during metastatic breast cancer treatment do you typically screen for brain metastases?
  • How do you view the role of systemic therapy versus local therapy in the management of brain metastases in HER2-positive mBC?